Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference September 20, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences August 30, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium August 21, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in a Poster Presentation at the 2018 Military Health System Research Symposium August 15, 2018 • 11:46 AM EDT
Tonix Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights August 13, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Outcome of Interim Analysis for Phase 3 HONOR Study of Tonmya® in Military-Related PTSD July 27, 2018 • 8:00 AM EDT
Tonix Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for TNX-102 SL for Treatment of Agitation in Alzheimer’s Disease July 16, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Presented New Data Related to Suicidal Ideation and Behaviors in Military-Related PTSD from the Phase 2 AtEase Study at the American Society of Clinical Psychopharmacology May 31, 2018 • 4:30 PM EDT
